Krystal Biotech Company Insiders
KRYS Stock | USD 188.61 0.57 0.30% |
Krystal Biotech's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Krystal Biotech suggests that vertually all insiders are panicking. Krystal Biotech employs about 275 people. The company is managed by 19 executives with a total tenure of roughly 642 years, averaging almost 33.0 years of service per executive, having 14.47 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-03-13 | Suma Krishnan | Disposed 25000 @ 177.79 | View | ||
2025-02-27 | Kathryn Romano | Disposed 750 @ 175.22 | View | ||
2024-12-13 | Suma Krishnan | Disposed 25000 @ 164.78 | View | ||
2024-09-12 | Suma Krishnan | Disposed 25000 @ 197.76 | View | ||
2024-06-11 | Suma Krishnan | Disposed 25000 @ 175.76 | View | ||
2024-05-20 | Julian S. Gangolli | Disposed 20000 @ 164.13 | View |
Monitoring Krystal Biotech's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Krystal |
Krystal Biotech's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Krystal Biotech's future performance. Based on our forecasts, it is anticipated that Krystal will maintain a workforce of slightly above 280 employees by April 2025.Krystal Biotech Management Team Effectiveness
The company has return on total asset (ROA) of 0.0688 % which means that it generated a profit of $0.0688 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1034 %, meaning that it created $0.1034 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.09 in 2025. Return On Capital Employed is likely to gain to 0.07 in 2025. At this time, Krystal Biotech's Asset Turnover is comparatively stable compared to the past year.Common Stock Shares Outstanding is likely to drop to about 19.6 M in 2025. Net Loss is likely to gain to about (119.7 M) in 2025
Krystal Biotech Workforce Comparison
Krystal Biotech is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,346. Krystal Biotech retains roughly 275 in number of employees claiming about 12% of equities under Health Care industry.
Krystal Biotech Profit Margins
The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.45.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.73 | 0.9309 |
|
|
Krystal Biotech Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Krystal Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Krystal Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Krystal Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.4 | 18 | 45 | 282,900 | 286,558 |
2024-06-01 | 0.1944 | 7 | 36 | 50,000 | 140,000 |
2024-03-01 | 0.4648 | 33 | 71 | 216,800 | 201,290 |
2023-06-01 | 0.2295 | 14 | 61 | 86,180 | 453,428 |
2023-03-01 | 0.2813 | 9 | 32 | 193,600 | 171,723 |
2022-03-01 | 2.0 | 6 | 3 | 418,600 | 9,409 |
2021-06-01 | 2.0 | 6 | 3 | 239,000 | 37,898 |
2020-06-01 | 0.2308 | 3 | 13 | 20,400 | 100,000 |
2020-03-01 | 0.1429 | 2 | 14 | 175,000 | 65,398 |
2019-12-01 | 0.0435 | 1 | 23 | 6,250 | 106,250 |
2017-09-01 | 0.6364 | 7 | 11 | 872,471 | 1,510,269 |
Krystal Biotech Notable Stakeholders
A Krystal Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Krystal Biotech often face trade-offs trying to please all of them. Krystal Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Krystal Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Suma Krishnan | President Founder | Profile | |
Josh Suskin | Director Operations | Profile | |
Christine Wilson | Head Marketing | Profile | |
David Chien | Senior Development | Profile | |
Hubert MD | Senior Development | Profile | |
Gloria Lin | Accounting Mang | Profile | |
Kathryn Romano | Executive Officer | Profile | |
Katherine Tuminello | HR Mang | Profile | |
Stephane Paquette | Vice Development | Profile | |
Jennifer McDonough | Analytics Access | Profile | |
MS MBA | Chairman, Founder | Profile | |
John Karakkal | Vice Marketing | Profile | |
Ram Kamineni | Senior Operations | Profile | |
David Glynn | Commercial Counsel | Profile | |
John Thomas | General Secretary | Profile | |
Laurent Goux | Senior Europe | Profile | |
Andreas Orth | Ex Officer | Profile | |
Meg Dodge | Vice Communications | Profile | |
Kathryn CPA | Executive Officer | Profile |
About Krystal Biotech Management Performance
The success or failure of an entity such as Krystal Biotech often depends on how effective the management is. Krystal Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Krystal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Krystal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.08 | 0.09 | |
Return On Capital Employed | 0.07 | 0.07 | |
Return On Assets | 0.08 | 0.09 | |
Return On Equity | 0.09 | 0.10 |
Please note, the imprecision that can be found in Krystal Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Krystal Biotech. Check Krystal Biotech's Beneish M Score to see the likelihood of Krystal Biotech's management manipulating its earnings.
Krystal Biotech Workforce Analysis
Traditionally, organizations such as Krystal Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Krystal Biotech within its industry.Krystal Biotech Manpower Efficiency
Return on Krystal Biotech Manpower
Revenue Per Employee | 1.1M | |
Revenue Per Executive | 15.3M | |
Net Income Per Employee | 324.2K | |
Net Income Per Executive | 4.7M | |
Working Capital Per Employee | 2.3M | |
Working Capital Per Executive | 33.7M |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.